VOLITIONRX LTD

VNRX

VOLITIONRX LTD

VNRX

Insider Sentiment (TTM):

Last Purchase:2025-11-17Last Sale:2024-01-02Shares Purchased (TTM):289,229Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:22,375,280Shares Outstanding:7,930,612Institutional Ownership Pct.:282.14%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	3	3	1	0	2	3	3	5	6	12	21	11
Assets Current
Assets Current	4	5	2	1	3	3	4	7	7	13	22	12
Accounts Receivable Net Current	0	0	0	0	0	0	0	0	0	0	0	0
Prepaid Expense Current	1	1	0	0	0	0	0	1	1	1	1	1
Other Assets Current	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Net	4	4	4	4	5	4	4	5	5	5	6	5
Operating Lease Right Of Use Asset	0	0	0	1	1	1	1	1	1	1	1	0
Intangible Assets Net Excluding Goodwill	-	-	-	-	-	-	-	-	-	0	0	0
Finite Lived Intangible Assets Net	0	0	0	0	0	0	0	0	0	-	0	-
Assets	8	9	7	6	9	9	9	13	13	19	28	18
Liabilities And Stockhold…
Accounts Payable Current	4	4	3	3	2	3	3	2	3	4	3	3
Accrued Liabilities Current	3	4	4	5	4	4	3	3	3	3	4	3
Deferred Revenue Current	0	0	0	0	0	0	0	23	23	23	0	10
Management Fee Payable	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current
Liabilities Current	13	14	12	11	9	8	8	30	31	31	9	18
Long Term Debt Current	1	1	1	1	1	1	1	1	1	1	1	1
Finance Lease Liability Current	-	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Contract With Customer Liability	-	-	-	-	-	-	-	-	-	0	0	0
Contract With Customer Liability Current	-	-	-	-	-	-	0	0	0	-	0	-
Derivative Liabilities Current	2	1	1	0	1	-	0	-	-	-	-	-
Convertible Notes Payable Current	3	3	2	2	0	-	0	-	-	-	-	-
Long Term Debt Noncurrent	6	6	6	6	6	6	4	4	4	3	4	2
Deferred Revenue Noncurrent	21	21	22	22	23	23	23	-	-	-	-	-
Finance Lease Liability Noncurrent	-	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Convertible Long Term Notes Payable	0	0	1	2	3	-	0	-	-	-	-	-
Liabilities Noncurrent	28	29	-	31	33	29	-	5	5	5	-	3
Liabilities	42	42	42	42	42	38	36	35	36	36	37	21
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	235	228	219	212	210	207	204	202	196	195	194	192
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	-0	-0	-0	0	0	0	0	0	0	0
Retained Earnings Accumulated Deficit	-267	-260	-253	-247	-241	-235	-230	-224	-218	-211	-203	-194
Stockholders Equity	-34	-33	-34	-35	-32	-28	-25	-22	-22	-17	-9	-2
Minority Interest	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1	-1
Liabilities And Stockholders Equity	8	9	7	6	9	9	9	13	13	19	28	18
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	325	325	325	325	325	175	325	175	100	100	175	100
Common Stock Shares Issued	12	8	6	5	5	5	5	5	4	4	4	4
Shares Outstanding	12	8	6	5	5	5	5	5	4	4	4	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-18.64%	-36.36%	-63.64%	-	-	-	-	-	-	-	-	-
2025	22.22%	64.44%	42.22%	-6.25%	1.56%	-32.81%	-14.29%	-22.86%	-17.14%	-30.00%	-21.75%	-64.25%
2024	-22.73%	-29.55%	-27.27%	27.27%	60.00%	9.09%	-12.50%	-6.94%	-16.67%	-14.04%	-8.77%	61.40%
2023	-	-	-	4.07%	-41.46%	-34.15%	-16.88%	23.38%	40.26%	-13.89%	6.94%	-1.39%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.30	0.33	0.17	0.12	0.35	0.40	0.52	0.22	0.24	0.43	2.44	0.69
Quick Ratio	0.25	0.27	0.13	0.08	0.30	0.37	0.48	0.20	0.21	0.39	2.39	0.64
Working Capital	-9.40M	-9.05M	-10.17M	-10.09M	-5.98M	-4.98M	-3.73M	-23.48M	-23.63M	-18.02M	12.91M	-5.46M
Leverage & Debt
Debt to Equity	-1.25	-1.27	-1.19	-1.18	-1.26	-1.29	-1.36	-1.56	-1.57	-2.17	-4.21	-7.33
Interest Coverage TTM	-22.42	-86.54	-98.80	-103.18	-106.67	-249.95	-	-	-	-	-	-
Debt Ratio	5.04	4.69	6.16	6.57	4.80	4.41	3.78	2.79	2.75	1.86	1.31	1.16
Efficiency & Turnover
Asset Turnover TTM	0.29	0.28	0.21	0.15	0.12	0.09	0.07	0.08	0.05	0.04	0.03	0.03
Days Sales Outstanding TTM	34.67	32.57	45.26	77.08	49.23	44.82	52.26	49.26	67.79	57.72	74.20	11.19
Receivables Turnover TTM	10.53	11.21	8.06	4.74	7.41	8.14	6.98	7.41	5.38	6.32	4.92	32.61
Per Share Metrics
Diluted EPS TTM	-2.80	-3.57	-4.37	-4.29	-4.61	-5.05	-6.30	-6.80	-7.84	-8.52	-9.92	-
Free Cash Flow Per Share TTM	-1.63	-2.62	-3.14	-3.61	-4.17	-4.39	-5.45	-3.14	-4.27	-4.52	-4.68	-8.08
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-790.22%	-874.50%	-1,258.47%	-1,542.24%	-1,779.01%	-1,846.75%	-2,190.90%	-2,331.90%	-3,355.66%	-4,432.36%	-4,641.76%	-5,415.58%
Net Profit Margin TTM	-1,042.09%	-996.89%	-1,352.16%	-1,577.61%	-1,793.88%	-1,862.42%	-2,209.79%	-2,323.23%	-3,320.12%	-4,379.63%	-4,555.53%	-5,228.68%
Growth Metrics
Net Revenue Growth (1Y)	86.32%	88.49%	40.04%	14.48%	35.10%	64.15%	59.10%	97.50%	88.32%	133.06%	153.04%	224.04%
Net Income Growth (1Y)	8.24%	0.89%	-14.31%	-22.26%	-27.01%	-30.19%	-22.82%	-12.24%	-3.17%	9.96%	15.43%	8.80%
EPS Growth (1Y)	-53.28%	-35.92%	-34.53%	-34.48%	-41.79%	-43.11%	-34.23%	-25.59%	-8.77%	-15.48%	-18.43%	-20.15%
Valuation Metrics
P/E TTM	-0.63	-1.29	-1.40	-3.21	-3.34	-2.36	-2.12	-1.86	-1.56	-1.79	-1.67	-1.59
P/B TTM	-0.48	-0.95	-0.92	-2.07	-2.39	-1.98	-2.21	-2.45	-2.21	-3.75	-6.77	-18.96
P/S TTM	6.61	12.86	18.93	50.64	59.90	43.89	46.74	43.11	51.80	78.29	76.06	83.03
Market Cap	16.26M	31.72M	32.70M	74.54M	79.03M	57.43M	57.66M	55.44M	50.59M	62.40M	58.97M	54.06M
Enterprise Value	23.94M	39.29M	40.77M	82.40M	83.78M	61.27M	59.25M	54.87M	49.54M	55.20M	43.12M	46.64M
Calculated Values
Free Cash Flow TTM	-19.58M	-20.76M	-19.77M	-19.77M	-21.67M	-22.10M	-26.17M	-14.53M	-17.69M	-18.57M	-19.15M	-31.67M
Net Debt	7.68M	7.56M	8.06M	7.86M	4.75M	3.84M	1.60M	-561.19K	-1.04M	-7.20M	-15.85M	-7.42M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-11-17Purchase

Owner: Reynolds, Cameron John

Title: President and CEO

Shares: 20,000

Price/Share: $0.35

Value: $7,000.00

Shares Owned: 2,554,847

Relationship: Director,Officer

Ownership: Direct

2025-10-14Purchase

Owner: Reynolds, Cameron John

Title: President and CEO

Shares: 110,000

Price/Share: $0.51

Value: $56,100.00

Shares Owned: 2,534,847

Relationship: Director,Officer

Ownership: Direct

2025-10-14Purchase

Owner: Still, Timothy I

Title: -

Shares: 48,076

Price/Share: $0.51

Value: $24,518.76

Shares Owned: 1,535,458

Relationship: Director

Ownership: Direct

2025-10-14Purchase

Owner: Innes, Guy Archibald

Title: -

Shares: 96,153

Price/Share: $0.51

Value: $49,038.03

Shares Owned: 1,062,967

Relationship: Director

Ownership: Direct

2025-09-12Purchase

Owner: Reynolds, Cameron John

Title: President and CEO

Shares: 15,000

Price/Share: $0.66

Value: $9,900.00

Shares Owned: 2,624,847

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-11-17	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	20,000	0.35	$7,000.00	2,554,847	4
2025-10-14	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	110,000	0.51	$56,100.00	2,534,847	4
2025-10-14	Still, Timothy I	Director	-	Direct	Purchase	48,076	0.51	$24,518.76	1,535,458	4
2025-10-14	Innes, Guy Archibald	Director	-	Direct	Purchase	96,153	0.51	$49,038.03	1,062,967	4
2025-09-12	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	15,000	0.66	$9,900.00	2,624,847	4
2025-08-05	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	78,125	0.64	$50,000.00	2,609,847	4
2025-08-05	Innes, Guy Archibald	Director	-	Direct	Purchase	78,125	0.64	$50,000.00	966,814	4
2025-06-12	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	12,500	0.59	$7,375.00	2,331,722	4
2025-06-03	Innes, Guy Archibald	Director	-	Direct	Purchase	20,000	0.54	$10,800.00	888,689	4
2025-05-19	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	20,000	0.44	$8,800.00	2,319,222	4
2025-05-19	Micallef, Jacob Vincent	Officer	Chief Scientific Officer	Direct	Purchase	50,000	0.43	$21,500.00	426,033	4
2025-03-26	Innes, Guy Archibald	Director	-	Direct	Purchase	181,818	0.55	$99,999.90	868,689	4
2025-03-26	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	181,818	0.55	$99,999.90	2,299,222	4
2024-12-09	Micallef, Jacob Vincent	Officer	Chief Scientific Officer	Direct	Purchase	43,691	0.57	$24,903.87	394,352	4
2024-12-09	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	139,811	0.57	$79,692.27	2,117,404	4
2024-12-09	Innes, Guy Archibald	Director	-	Direct	Purchase	174,764	0.57	$99,615.48	617,085	4
2024-12-09	Still, Timothy I	Director	-	Direct	Purchase	87,382	0.57	$49,807.74	1,487,382	4
2024-08-20	Innes, Guy Archibald	Director	-	Direct	Purchase	150,000	0.67	$100,500.00	406,683	4
2024-01-02	Eight, Corp Ltd, Hever In…	TenPercentOwner	-	Indirect	Sale	20,000	0.90	$18,000.00	298,419	4
2023-12-18	Butera, Salvatore Thomas	Officer	CEO - Volition Veterinary	Direct	Purchase	10,000	0.83	$8,300.00	99,350	4
2023-12-15	Hever, Investments Ltd, E…	TenPercentOwner	-	Indirect	Sale	20,000	0.75	$15,000.00	318,419	4
2023-12-15	Butera, Salvatore Thomas	Officer	CEO - Volition Veterinary	Direct	Purchase	10,000	0.77	$7,700.00	89,350	4
2023-12-13	Rootsaert, Rodney Gerard	Officer	Secretary	Direct	Purchase	10,000	0.60	$6,000.00	78,652	4
2023-12-08	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	10,000	0.67	$6,700.00	1,704,518	4
2023-11-27	Innes, Guy Archibald	Director	-	Direct	Purchase	20,000	0.77	$15,400.00	627,161	4
2023-11-27	Futcher, Edward	Director	-	Direct	Purchase	9,000	0.80	$7,200.00	71,936	4
2023-11-24	Innes, Guy Archibald	Director	-	Direct	Purchase	10,000	0.76	$7,600.00	607,161	4
2023-11-22	Innes, Guy Archibald	Director	-	Direct	Purchase	20,000	0.71	$14,200.00	597,161	4
2023-11-16	Butera, Salvatore Thomas	Officer	CEO - Volition Veterinary	Direct	Purchase	10,000	0.81	$8,100.00	79,350	4
2023-09-05	Barnes, Phillip	Director	-	Direct	Purchase	5,000	1.30	$6,500.00	24,686	4
2023-08-31	Faulkes, Martin Charles	Director	-	Direct	Purchase	9,716	1.28	$12,436.48	1,673,532	4
2023-08-31	Henshall, Mickie	Director	-	Direct	Purchase	3,706	1.25	$4,632.50	18,706	4
2023-08-30	Micallef, Jacob Vincent	Officer	Chief Scientific Officer	Indirect	Purchase	8,750	1.27	$11,112.50	55,000	4
2023-08-25	Micallef, Jacob Vincent	Officer	Chief Scientific Officer	Direct	Purchase	20,000	1.24	$24,800.00	235,140	4
2023-08-24	Michel, Gaetan	Officer	Chief Operating Officer	Direct	Purchase	5,000	1.23	$6,150.00	212,997	4
2023-08-24	Kway, Jasmine	Officer	CEO - Singapore Volition	Indirect	Purchase	5,000	1.20	$6,000.00	10,400	4
2023-08-24	Futcher, Edward	Director	-	Direct	Purchase	5,000	1.22	$6,100.00	62,936	4
2023-08-16	Butera, Salvatore Thomas	Officer	CEO - Volition Veterinary	Direct	Purchase	8,000	1.21	$9,680.00	69,350	4
2023-08-16	Reynolds, Cameron John	Director,Officer	President and CEO	Direct	Purchase	10,000	1.22	$12,200.00	1,494,518	4
2023-06-02	Butera, Salvatore Thomas	Officer	CEO - Volition Veterinary	Direct	Purchase	10,000	1.59	$15,900.00	61,350	4
2023-02-22	Innes, Guy Archibald	Director	-	Indirect	Purchase	234,000	1.75	$409,500.00	154,504	4
2022-12-19	Butera, Salvatore Thomas	Officer	CEO - Volition Veterinary	Direct	Purchase	5,000	2.27	$11,350.00	51,350	4
2022-12-19	Micallef, Jacob Vincent	Officer	Chief Scientific Officer	Direct	Purchase	25,000	2.30	$57,500.00	188,392	4
2022-12-16	Faulkes, Martin Charles	Director	-	Direct	Purchase	55,000	2.10	$115,500.00	1,637,068	4
2022-12-12	Butera, Salvatore Thomas	Officer	CEO - Volition Veterinary	Direct	Purchase	4,350	2.09	$9,091.50	46,350	4
2022-12-08	Plummer, Nicholas	Officer	GC - Volition Diagnostics	Direct	Purchase	4,800	2.07	$9,936.00	51,494	4
2022-11-28	Butera, Salvatore Thomas	Officer	CEO - Volition Veterinary	Direct	Purchase	5,000	2.21	$11,050.00	42,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

282.14%

Inst. Shares: 22,375,280

Shares Outstanding: 7,930,612

2025-12-31

12.72%

Inst. Shares: 15,994,460

Shares Outstanding: 125,779,769

2025-09-30

23.78%

Inst. Shares: 26,067,933

Shares Outstanding: 109,620,405

2025-06-30

23.06%

Inst. Shares: 23,973,179

Shares Outstanding: 103,982,020

2025-03-31

20.85%

Inst. Shares: 21,008,583

Shares Outstanding: 100,746,467

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	22,375,280	7,930,612	282.14%
2025-12-31	15,994,460	125,779,769	12.72%
2025-09-30	26,067,933	109,620,405	23.78%
2025-06-30	23,973,179	103,982,020	23.06%
2025-03-31	21,008,583	100,746,467	20.85%
2024-12-31	18,677,706	96,097,485	19.44%
2024-09-30	17,526,713	92,392,570	18.97%
2024-06-30	7,991,589	82,928,314	9.64%
2024-03-31	7,785,670	82,108,972	9.48%
2023-12-31	6,339,743	81,898,321	7.74%
2023-09-30	6,298,144	78,342,417	8.04%
2023-06-30	6,451,635	78,136,364	8.26%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

VOLITIONRX LTD (VNRX) — SEC Financial Statements & Analysis

VOLITIONRX LTD (VNRX) is a in vitro & in vivo diagnostic substances company, incorporated in DE. VOLITIONRX LTD trades on NYSE as: VNRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), VOLITIONRX LTD reported a 86.32% year-over-year revenue growth, a Debt-to-Equity ratio of -1.25x, a Price-to-Sales (P/S) ratio of 6.61x (TTM), a Price-to-Book (P/B) ratio of -0.48x (TTM), at a market cap of $16.26M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 86.32%
Debt To Equity: -1.25x
P/S TTM: 6.61x
P/B TTM: -0.48x
Market Cap: $16.26M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is VOLITIONRX LTD in?

VOLITIONRX LTD (VNRX) operates in the In Vitro & In Vivo Diagnostic Substances industry.

What is VNRX's market cap?

VOLITIONRX LTD (VNRX) has a market capitalization of $16.26M as of 2026-06-30.

What exchange does VNRX trade on?

VOLITIONRX LTD (VNRX) trades on the NYSE.

Where is VOLITIONRX LTD incorporated?

VOLITIONRX LTD is incorporated in DE.

VOLITIONRX LTD

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

VOLITIONRX LTD (VNRX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in In Vitro & In Vivo Diagnostic Substances

Wall Street's data.
Main Street's price.

VOLITIONRX LTD (VNRX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in In Vitro & In Vivo Diagnostic Substances

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.